← SynDRA
BUSULFAN
SynDRA canonical compound SYN0002037 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Mechanism of action | DNA inhibitor |
|---|
| Indication | chronic myeloid leukemia (CML) |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
Mechanisms of action (all sources)
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ESR1
- ACHE
- LMNA
- NPY2R
- NPY1R
- NFE2L2
- MMP1
- MLNR
- MC5R
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- MAOA
- LCK
- HDAC6
- KDM4E
- KDM4A
- KCNH2
- HTR6
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- NR1I2
- NR3C1
- OPRD1
- SIGMAR1
- USP2
- TSHR
- TDP1
- TBXAS1
- TACR2
- TACR1
- SLCO1B3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2CJ
- CP2D6
- ESRRA
- KISSR
- NTM1A
- NTMT1
Drug classes
- Alkylating Activity
- Alkylating Drug
- Alkylating Agents
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Immunologic Factors
- Immunosuppressive Agents
- Myeloablative Agonists
- Noxae
ATC classes
Cross-references
Synonyms
- BUSULFEX
- Busulfex
- MYLERAN
- Myleran
- busilvex
- busulfex
- busulphan
- citosulfan
- glyzophrol
- leucosulfan
- sulphabutin
- Busulfano
- Busulfanum
- Leucosulfan
- Myelosan
- Myelosanum
- Sulphabutin
- NCI-C01592
- NSC-750
- Busilvex
- Busulfan fresenius kabi
- Busulphan
- Busulphane
- Butanedioldimethanesulfonate
- Buzulfan
- Citosulfan
- Glyzophrol
- Mablin
- Methanesulfonic
- Mielevcin
- Mielosan
- Mielucin
- Milecitan
- Mileran
- Misulban
- Mitosan
- Mitostan
Reported adverse events
- Cataract
- Infection
- Myelosuppression
- Pneumonia
- Rash
- Seizure
- Cardiac tamponade
Look up BUSULFAN in the interactive SynDRA portal →